Published in J Pers Med on October 30, 2012
The potential impact of pharmacogenetic testing on medication adherence. Pharmacogenomics J (2013) 1.64
Strengths and limitations of microarray-based phenotype prediction: lessons learned from the IMPROVER Diagnostic Signature Challenge. Bioinformatics (2013) 1.39
Pilot study of pharmacist-assisted delivery of pharmacogenetic testing in a primary care setting. Pharmacogenomics (2014) 0.96
Clinical delivery of pharmacogenetic testing services: a proposed partnership between genetic counselors and pharmacists. Pharmacogenomics (2013) 0.89
Toward clinical genomics in everyday medicine: perspectives and recommendations. Expert Rev Mol Diagn (2016) 0.89
Comparison of delivery strategies for pharmacogenetic testing services. Pharmacogenet Genomics (2014) 0.87
Pharmacogenetic testing: Current Evidence of Clinical Utility. Ther Adv Drug Saf (2013) 0.87
Payer decision making for next-generation sequencing-based genetic tests: insights from cell-free DNA prenatal screening. Genet Med (2016) 0.82
Clinical usefulness of gene-expression profile to rule out acute rejection after heart transplantation: CARGO II. Eur Heart J (2016) 0.79
Documenting Pharmacogenomic Testing with CPT Codes. J AHIMA (2016) 0.79
Routine screening for CYP2C19 polymorphisms for patients being treated with clopidogrel is not recommended. Hawaii J Med Public Health (2015) 0.78
Barriers to clinical adoption of next generation sequencing: Perspectives of a policy Delphi panel. Appl Transl Genom (2016) 0.75
Psychiatric Pharmacogenomics: How Close Are We? Biol Psychiatry (2016) 0.75
CYP2C19 genetic variation and individualized clopidogrel prescription in a cardiology clinic. J Community Hosp Intern Med Perspect (2017) 0.75
Payer coverage policies for multigene tests. Nat Biotechnol (2017) 0.75
Gene-expression signatures in breast cancer. N Engl J Med (2009) 9.23
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA (2009) 6.80
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet (2008) 6.41
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med (2010) 4.73
The evidence dilemma in genomic medicine. Health Aff (Millwood) (2008) 3.58
Coverage options for promising technologies: Medicare's 'coverage with evidence development'. Health Aff (Millwood) (2006) 2.79
Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA (2011) 2.57
Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use. Pharmacotherapy (2008) 2.34
Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol (2010) 2.03
Personalized medicine: factors influencing reimbursement. Health Policy (2009) 1.90
Clinical and ethical considerations in pharmacogenetic testing: views of physicians in 3 "early adopting" departments of psychiatry. J Clin Psychiatry (2010) 1.83
Personalizing medicine with clinical pharmacogenetics. Genet Med (2011) 1.73
The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc Interv (2008) 1.63
Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. J Clin Pharm Ther (2007) 1.42
U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey. Pharmacoepidemiol Drug Saf (2009) 1.34
Stakeholder assessment of the evidence for cancer genomic tests: insights from three case studies. Genet Med (2012) 1.32
Survey of US public attitudes toward pharmacogenetic testing. Pharmacogenomics J (2011) 1.27
Pharmacogenomics, evidence, and the role of payers. Public Health Genomics (2009) 1.26
Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J (2010) 1.25
The long and winding road to warfarin pharmacogenetic testing. J Am Coll Cardiol (2010) 1.20
Coverage policy development for personalized medicine: private payer perspectives on developing policy for the 21-gene assay. J Oncol Pract (2010) 1.14
Availability of pharmacogenomics-based prescribing information in drug package inserts for currently approved drugs. Pharmacogenomics J (2004) 1.12
Public perspectives about pharmacogenetic testing and managing ancillary findings. Genet Test Mol Biomarkers (2011) 1.11
Health technology assessment and private payers' coverage of personalized medicine. J Oncol Pract (2011) 1.10
Real-world clinical effectiveness, regulatory transparency and payer coverage: three ingredients for translating pharmacogenomics into clinical practice. Pharmacogenomics (2010) 1.08
Evidence and practice regarding the role for CYP2D6 inhibition in decisions about tamoxifen therapy. J Clin Oncol (2010) 1.06
Gene expression profiling distinguishes a molecular signature for grade 1B mild acute cellular rejection in cardiac allograft recipients. J Heart Lung Transplant (2007) 1.00
Putting pharmacogenetics into practice. Nat Biotechnol (2006) 0.97
Pharmacogenetic testing in the United Kingdom genetics and immunogenetics laboratories. Genet Test Mol Biomarkers (2010) 0.93
Transplant vasculopathy is associated with increased AlloMap gene expression score. J Heart Lung Transplant (2007) 0.91
Post-transplant ischemic injury is associated with up-regulated AlloMap gene expression. Clin Transplant (2007) 0.89
Clinical implications and longitudinal alteration of peripheral blood transcriptional signals indicative of future cardiac allograft rejection. J Heart Lung Transplant (2008) 0.89
HLA-B*5701 clinical testing: early experience in the United States. Pharmacogenet Genomics (2007) 0.88
Payer perspectives on pharmacogenomics testing and drug development. Pharmacogenomics (2009) 0.88
Personalized medicine and disruptive innovation: implications for technology assessment. Genet Med (2009) 0.80